Neurotoxicity associated with ALK inhibitors in the treatment of non-small cell lung cancer: an analysis of the FAERS database
Open Access
- 3 November 2026
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 17, 1852087
Abstract
Background: ALK inhibitors (ALKis) have substantially improved outcomes in ALK-positive non-small cell lung cancer (NSCLC). Neurological adverse events (AEs) remain clinically relevant, but their reporting patterns and reported time-to-onset (TTO) characteristics in routine pharmacovigilance require further characterization. Methods: Neurological AE reports recorded with five ALK inhibitors (crizotinib, ceritinib, alectinib, brigatinib, and lorlatinib) were extracted from FAERS (Q1 2004–Q1 2025). Reporting disproportionality was evaluated at the preferred-term (PT) level using the reporting odds ratio (ROR), proportional reporting ratio (PRR), and Bayesian confidence propagation neural network (BCPNN). TTO analyses were restricted to reports with evaluable timing information, and exploratory subgroup analyses characterized reporting-signal patterns by age, sex, and reporter type. Results: The final analysis included 1,473 report-level reports and 2,274 PT-level neurological AE records; one report could contain more than one PT. Lorlatinib, ceritinib, brigatinib, crizotinib, and alectinib had 29, 15, 12, 9, and 9 PTs, respectively, that met all three disproportionality criteria. Among the 1,473 reports, 577 (39.17%) had evaluable TTO information. Recorded onset times among these evaluable reports were more concentrated in the earlier period after treatment initiation, but this distribution does not estimate incidence, absolute risk, or hazard among all exposed patients. Conclusion: This pharmacovigilance analysis identifies drug-specific patterns of reported neurological AEs and reported TTO among ALK inhibitors. The findings support clinical awareness and hypothesis generation, but they do not establish causality or comparative clinical safety and should be evaluated in studies with exposure denominators and control of confounding.Keywords
Funding Information
- Project of the China Association for Promotion of Health Science and Technology (JKHY2023003)
- Key Clinical Projects of Peking University Third Hospital (BYSYZD2025049)
- Key Clinical Projects of Peking University Third Hospital (BYSYRCYJ2023001)
This publication has 34 references indexed in Scilit:
- Update advances in anaplastic lymphoma kinase‐positive non–small cell lung cancer treatmentCancer, 2025
- Expert Consensus on the Management of Adverse Events of Lorlatinib in the Treatment of ALK+ Advanced Non-small Cell Lung CancerClinical Drug Investigation, 2024
- Safety of immune checkpoint inhibitors: An updated comprehensive disproportionality analysis and meta-analysisCritical Reviews in Oncology/Hematology, 2024
- The Reporting of a Disproportionality Analysis for Drug Safety Signal Detection Using Individual Case Safety Reports in PharmacoVigilance (READUS-PV): Development and StatementDrug Safety, 2024
- The REporting of A Disproportionality Analysis for DrUg Safety Signal Detection Using Individual Case Safety Reports in PharmacoVigilance (READUS-PV): Explanation and ElaborationDrug Safety, 2024
- Bilateral optic neuropathy associated with lorlatinib monotherapy for ALK-positive metastatic lung adenocarcinomaAmerican Journal of Ophthalmology Case Reports, 2024
- Detection Algorithms for Simple Two-Group Comparisons Using Spontaneous Reporting SystemsDrug Safety, 2024
- Psychiatric disorders associated with immune checkpoint inhibitors: a pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) databaseeClinicalMedicine, 2023
- Neurotoxicity of methamphetamine: Main effects and mechanismsExperimental Neurology, 2021
- A Bayesian neural network method for adverse drug reaction signal generationEuropean Journal of Clinical Pharmacology, 1998